title: Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency.
abstract: Overactive bladder is a highly prevalent disorder with a significant impact on quality of life. Antimuscarinic agents are commonly used, but persistence is limited due to unsatisfactory efficacy and/or tolerability. Mirabegron is the first beta-3 adrenoceptor agonist approved for the treatment of overactive bladder syndrome. This paper reviews the pharmacology, mechanism of action, efficacy, and safety of mirabegron. A PubMed search of all English articles pertaining to mirabegron was performed. An alternative to antimuscarinics, mirabegron has a unique mechanism, improves overactive bladder symptoms and quality of life, and has limited adverse effects and few contraindications.
authors.affiliation: University of Massachusetts Medical School, Worcester, MA, USA.
authors.forename: Raymond T
authors.initials: RT
authors.lastname: Lee
authors.affiliation: UMass Memorial Medical Center, University of Massachusetts Medical School, Worcester, MA, USA.
authors.forename: Mitchell
authors.initials: M
authors.lastname: Bamberger
authors.affiliation: Division of Urology/Surgery, Warren Alpert Medical School of Brown University, Providence, RI, USA.
authors.forename: Pamela
authors.initials: P
authors.lastname: Ellsworth
keywords: beta-3 agonist; incontinence; mirabegron; overactive bladder